Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $250.0 million
Deal Type : Public Offering
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
Details : The net proceeds will be used in the development of AG10 (acoramidis HCl). Which is being evaluated in the Phase III clinical trial studies for the treatment of Transthyretin Amyloid Cardiomyopathy.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 04, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $250.0 million
Deal Type : Public Offering
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
Details : BridgeBio grants Bayer an exclusive license to commercialize acoramidis, a small molecule stabilizer of TTR for ATTR-CM patients in Europe.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : $310.0 million
March 04, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Acquisition
Bayer Strengthens Pharma Portfolio with New Cardiology Drug Acoramidis
Details : Bayer acquires commercialization rights for AG10 (acoramidis), an oral transthyretin stabilizer for ATTR CM in Europe.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 04, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Alexion Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
BridgeBio Reports Positive Results for Acoramidis in ATTR-CM Phase 3 Study
Details : AG-10 (acoramidis) is an investigational, orally-administered small molecule stabilizer of transthyretin (TTR), evaluated in Phase 3 trials for Transthyretin Amyloid Cardiomyopathy treatment.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 02, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Alexion Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Blue Owl Capital
Deal Size : $500.0 million
Deal Type : Financing
BridgeBio Secures Up to $1.25 Billion from Blue Owl to Advance Genetic Drug Development
Details : The net proceeds will be used in the anticipated launch of AG10 (acoramidis HCl) as the potential backbone of therapy for transthyretin amyloid cardiomyopathy (ATTR-CM).
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : $500.0 million
January 18, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Blue Owl Capital
Deal Size : $500.0 million
Deal Type : Financing
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Qatar Investment Authority
Deal Size : $250.0 million
Deal Type : Private Placement
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
Details : The net proceeds will fund the launch of AG10 (acoramidis), an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), and company's upcoming Phase 3 readouts in achondroplasia, LGMD2I, and ADH1.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Qatar Investment Authority
Deal Size : $250.0 million
Deal Type : Private Placement
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Alexion Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 17, 2023
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Alexion Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co. LLC
Deal Size : $150.0 million
Deal Type : Public Offering
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
Details : The Company intend to use the proceeds from this offering to fund clinical and pre-clinical development of company's current and future product candidates including AG10 (acoramidis), conduct research activities, and for working capital and other general...
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 08, 2023
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co. LLC
Deal Size : $150.0 million
Deal Type : Public Offering
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co. LLC
Deal Size : $150.0 million
Deal Type : Public Offering
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
Details : The Company intend to use the proceeds from this offering to fund clinical and pre-clinical development of company's current and future product candidates including AG10 (acoramidis), conduct research activities, and for working capital and other general...
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 06, 2023
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co. LLC
Deal Size : $150.0 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?